Cargando…

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis

BACKGROUND: Progressive bone marrow fibrosis (BMF) is a cardinal feature of many myeloproliferative neoplasms (MPNs) and there is a documented association between the severity of BMF and overall prognosis. We conducted an exploratory analysis of sequential BMF data from two phase I studies of long-t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jamieson, Catriona, Hasserjian, Robert, Gotlib, Jason, Cortes, Jorge, Stone, Richard, Talpaz, Moshe, Thiele, Jürgen, Rodig, Scott, Pozdnyakova, Olga
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566296/ https://www.ncbi.nlm.nih.gov/pubmed/26357842 http://dx.doi.org/10.1186/s12967-015-0644-4

Ejemplares similares

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
por: Talpaz, Moshe, et al.
Publicado: (2020)

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
por: Pardanani, A, et al.
Publicado: (2015)

Clinical Utility of Fedratinib in Myelofibrosis
por: Waksal, Julian A, et al.
Publicado: (2021)

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
por: Harrison, Claire N., et al.
Publicado: (2022)

The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis
por: Palmer, Jeanne, et al.
Publicado: (2020)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
por: Harrison, Claire N., et al.
Publicado: (2020)

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Ogasawara, Ken, et al.
Publicado: (2019)

Primary myelofibrosis evolving to an aplastic appearing marrow
por: Schaefer, Jordan K., et al.
Publicado: (2018)

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
por: Harrison, Claire N., et al.
Publicado: (2021)

P1057: REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE
por: Harrison, C., et al.
Publicado: (2022)

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
por: Kvasnicka, Hans Michael, et al.
Publicado: (2018)

P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)
por: Gupta, V., et al.
Publicado: (2022)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
por: Gangat, Naseema, et al.
Publicado: (2023)

P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS
por: Palandri, Francesca, et al.
Publicado: (2023)

P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS
por: Kiladjian, J.-J., et al.
Publicado: (2022)

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
por: Gupta, V., et al.
Publicado: (2022)

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial
por: Mesa, Ruben A., et al.
Publicado: (2021)

P1058: REAL-WORLD OUTCOMES WITH FEDRATINIB THERAPY IN PATIENTS WITH PRIMARY MYELOFIBROSIS POST-RUXOLITINIB DISCONTINUATION
por: Passamonti, F., et al.
Publicado: (2022)

P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS
por: Jeyaraju, Danny, et al.
Publicado: (2023)

A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2017)

Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Fedratinib Attenuates Bleomycin-Induced Pulmonary Fibrosis via the JAK2/STAT3 and TGF-β1 Signaling Pathway
por: Ruan, Hao, et al.
Publicado: (2021)

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures
por: Singer, Jack W., et al.
Publicado: (2019)

JAK2 Inhibition by Fedratinib Reduces Osteoblast Differentiation and Mineralisation of Human Mesenchymal Stem Cells
por: AlMuraikhi, Nihal, et al.
Publicado: (2021)

Transfusion Independence Achieved with Combination Fedratinib and Luspatercept in an Elderly Man with Heavily Pretreated Intermediate-2 Risk Primary Myelofibrosis
por: Yun, Nicole K., et al.
Publicado: (2022)

Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis
por: Pardanani, Animesh, et al.
Publicado: (2021)

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
por: Harrison, Claire N., et al.
Publicado: (2016)

A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis
por: Luker, Gary D., et al.
Publicado: (2016)

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
por: Wu, Dandan, et al.
Publicado: (2020)

P1059: COMPARATIVE EFFICACY OF FEDRATINIB AND PACRITINIB FOR THE TREATMENT OF MYELOFIBROSIS IN PATIENTS WITH LOW PLATELET COUNTS: A SIMULATED TREATMENT COMPARISON STUDY
por: Tremblay, G., et al.
Publicado: (2022)

Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice
por: Ozono, Yoshinori, et al.
Publicado: (2020)

P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
por: Abraham, P., et al.
Publicado: (2022)

Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
por: Talpaz, Moshe, et al.
Publicado: (2018)

Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling
por: Reynolds, Samuel B., et al.
Publicado: (2023)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
Publicado: (2013)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

Myelofibrosis in 2019: moving beyond JAK2 inhibition
por: Schieber, Michael, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3h1vkagh8mrebaeghilj20910c